Notably, with the advent of novel drug classes such as GLP-1 RA and SGLT2i, the pharmacological approach to PAD in T2D might undergo—and probably already underwent—a significant watershed due to their CV benefits. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.